BioCentury | Dec 17, 2001
Product Development

Rituxan reaches out

...therapy with antibodies against the Rh-D red blood cell antigen). One alternative therapy is the Prosorba...
BioCentury | Jan 29, 2001
Company News

Cypress, Fresenius HemoCare GmbH sales and marketing update

...make Fresenius and its Fresenius HemoCare Inc. subsidiary (Redmond, Wash.) exclusive global distributors of CYPB's Prosorba...
BioCentury | Apr 10, 2000
Company News

Cypress, Fresenius HemoCare GmbH sales and marketing update

...CYPB partner Fresenius HemoCare launched in Europe CYPB's Prosorba protein A matrix plasmapheresis column to treat...
BioCentury | Apr 7, 2000
Company News

Cypress BioSciences launches Prosorba in Europe

...CYPB and partner Fresenius HemoCare (Bad Homburg, Germany) launched in Europe CYPB's Prosorba protein A matrix...
BioCentury | Mar 13, 2000
Clinical News

Prosorba Protein A matrix plasmapheresis column regulatory update

...Canada granted marketing approval for Prosorba to treat rheumatoid arthritis. Medexus Inc. (Toronto, Ontario) will market...
...Prosorba column to treat rheumatoid arthritis (RA). Cypress Bioscience Inc. (CYPB), San Diego, Calif. Product: Prosorba...
BioCentury | Mar 9, 2000
Company News

Cypress receives German marketing approval

...CYPB said partner Fresenius HemoCare (Bad Homburg, Germany) received the CE Mark for CYPB's Prosorba protein...
BioCentury | Dec 13, 1999
Company News

Cypress, Medexus Inc. sales and marketing update

...Prosorba column in Canada and will pay CYPB the lesser of the pre-determined percentage of Prosorba's...
...transfer price. Medexus also will conduct a trial in Canada for Canadian marketing approval of Prosorba...
...said the trial will partially fulfill a post-marketing study required by the FDA, which approved Prosorba...
BioCentury | Oct 18, 1999
Clinical News

Prosorba column: Phase III data; marketed to treat RA and ideopathic thrombocytopenic purpura (ITP)

...Rheumatism previously reported data from its 109-patient Phase III study in which 31.9 percent of Prosorba-treated...
...p=0.019) (see BioCentury Extra, Jan. 13, 1998). Cypress Bioscience Inc. (CYPB), San Diego, Calif. Product: Prosorba...
BioCentury | Aug 30, 1999
Clinical News

Prosorba column: Pilot data; marketed to treat RA and ideopathic thrombocytopenic purpura (ITP)

...15 patients with RA refractory to disease-modifying anti-rheumatic drugs (DMARDs). Patients in the study received Prosorba...
...after 20 weeks (8 weeks post treatment). Cypress Bioscience Inc. (CYPB), San Diego, Calif. Product: Prosorba...
BioCentury | Aug 16, 1999
Analyst Picks & Changes

Analyst picks & changes

..."strong buy" and a $6 price target. He said that increased awareness of CYPB's approved Prosorba...
Items per page:
1 - 10 of 74